Ann: Top 20 securityholders, page-93

First 93 Last

Share
Profile

Follow
abitlikeme

5,698 Posts.

82

11/03/19

19:14

Post #: 37724496
Share

Originally posted by Doole: ↑

Agreed that the RSPCA Vet has announced the SC-beating horse is well and truly dead - and most certainly that approach doesn't seem useful going forward, but please, be accurate. SC is not a scientist, never has been that I am aware - his history and qualifications are in the public domain so I won't side-track the conversation here. But please, be informed and accurate in your statements. His history speaks for itself. I stand by my perspective that we have paid a price for learning in more than one role at Sud and I admit that personally I do not support the CEO and Chairman's roles being held by the same person, particularly from a sh perspective. Just let's stay away from rose-colours ... because then HC seems to polarise over whether to look forward or quote history. Let's look forward without trying to re-write the past. Besides, if we don't have enough to launch with what we have now, we certainly won't survive financially until Anagrelide testing I wouldn't think.

Please also understand that SC is/was not the only person who was 'attracting' anything and we are still somewhat in the grey about the release of the 'sales guy'. The upgrading of this role is apparently in part due to the lack of success previously, but then as SC stated in one announcement, from memory, following a small success implied that was all him - without any mention of NW. However, we all seemed to have welcomed the upgrade and a kind of changing of the guard particularly for the US. Let's not get forgetful about all the players who have landed us where we are currently. Am I the only one who remembers that SC was one of the people who apparently had days booked solid in meetings with US Pharma.... then we ended up in China and South America.... I think a cheer-squad is not yet appropriate. And we seem to have forgotten what part has been played by the new guy in the increased credibility/interest.

I remain hopeful that the tech works, but would like to see our tech side release some results... We wait...

Expand

Good post Doole.

I think our man in N.Y. will deliver and some news is well and truly overdue.

SUD Price at posting: 0.5¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 47, 2024

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

DUI

Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

PYC

Scientific conference spotlights PYC's work on blindness disease treatment

LPE

Sales growth pushes Lovisa's fortunes (and shares) upwards

SIG

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

There are more pages in this discussion • 3 more messages in this thread...

First 93 Last

Add SUD (ASX) to my watchlist

Ann: Top 20 securityholders, page-93

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

HotCopper Highlights: Your most watched stocks for Week 47, 2024

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Scientific conference spotlights PYC's work on blindness disease treatment

Sales growth pushes Lovisa's fortunes (and shares) upwards

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse